ResearcherBeijing University of Chinese MedicineActive in the last 2 years
Yuchen Shi
Matched on ORCID iD 0000-0001-8642-7619; OpenAlex author ID A5041726479. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 4
- ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. Co-author DOI 10.1016/j.mcp.2025.102030↗
- Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8+ T cell infiltration. Co-author DOI 10.1080/2162402x.2025.2539442↗
- Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. Co-author DOI 10.1080/21691401.2023.2264358↗
- An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Co-author DOI 10.1038/s41467-022-33037-x↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hong-Juan Yao · 3 shared papers, 2022–2025 · strength 0.49
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030↗
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Liang Li · 3 shared papers, 2022–2025 · strength 0.49
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030↗
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Hebing Chen · 3 shared papers, 2022–2025 · strength 0.49
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030↗
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Xiaofei Zhou · 2 shared papers, 2022–2023 · strength 0.29
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Xiaoqiang Li · 1 shared paper, 2025 · strength 0.28
- Qifeng Xiao · 1 shared paper, 2025 · strength 0.20
- Chenyu Yuan · 1 shared paper, 2025 · strength 0.20
- Xiaohong Liu · 1 shared paper, 2025 · strength 0.20
- Xiaohong Liu · 1 shared paper, 2023 · strength 0.16
- Rong‐Guang Shao · 1 shared paper, 2022 · strength 0.13
- Rui Cao · 1 shared paper, 2022 · strength 0.13
- Yi Li · 1 shared paper, 2022 · strength 0.13
- Li Zhang · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.